SCHEMBL3350815

SCHEMBL3350815

O=[N+]([O-])c1cc(Nc2ncc(Br)c(Cl)n2)ccc1F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK17A Q9UEE5 2/20 0.45
ABCG2 Q9UNQ0 2/20 0.43
GSK3B P49841 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
MAPT P10636 4/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
LMNA P02545 2/20 0.41
SYK P43405 1/20 0.41
CA1 P00915 1/20 0.41
MMP2 P08253 1/20 0.41
CA14 Q9ULX7 1/20 0.41
HTT P42858 1/20 0.41
BRD4 O60885 1/20 0.41
CYP1A2 P05177 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3344400 0.86 MEN1 (0.43) STK17AABCG2GSK3BALDH1A1HDAC3
SCHEMBL3451191 0.83 ULK1 (0.45) ABCG2GSK3BALDH1A1HDAC3HDAC1
SCHEMBL3344858 0.81 MAPK1 (0.57) STK17ASYKCA1STK17B
SCHEMBL656938 0.80 AURKA (0.57) STK17AABCG2GSK3BMAPTMEN1
SCHEMBL30948594 0.79 ABCG2 (0.46) STK17AABCG2GSK3BALDH1A1HDAC3
SCHEMBL3348485 0.79 SMN1; SMN2 (0.50) ALDH1A1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL655435 0.75 NPC1 (0.55) ABCG2GSK3BALDH1A1MAPTMEN1
SCHEMBL656514 0.75 BRD4 (0.57) STK17AGSK3BMAPTMEN1KMT2A
SCHEMBL3448706 0.73 SYK (0.50) SYKCDK1
SCHEMBL28658309 0.73 MAPK9 (0.47) STK17AABCG2GSK3BBRD4STK17B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 WO disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD STK17A 1984/4885ABCG2 18/4885GSK3B 2904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.